负载聚唾液酸的纳米铝佐剂Pickering乳液增强疫苗接种效果
本研究制备了负载聚唾液酸(PSA)的纳米铝稳定Pickering乳液(NAPE/PSA),在25°C和40°C下物理稳定长达52周,蛋白负载效率高。体外实验显示NAPE和NAPE/PSA细胞相容性高,促进RAW264.7和DC2.4细胞对OVA的黏附与内吞,并上调TNF-α表达。免疫后第42天,NAPE和NAPE/PSA诱导的OVA特异性IgG1、IgG和IgG2a滴度与商业佐剂相当,且IgG和IgG2a滴度随时间持续升高。
要点
- NAPE/PSA在25°C和40°C下稳定52周,蛋白负载效率高。
- NAPE和NAPE/PSA促进细胞黏附、OVA内吞并上调TNF-α。
- 免疫后第42天IgG1、IgG、IgG2a滴度与商业佐剂相当。
核心结论
- NAPE或NAPE/PSA可作为兼具佐剂活性和抗原递送功能的潜在载体。
研究设计与样本
- 制备纳米铝锚定于油水界面的Pickering乳液(NAPE),并整合PSA和OVA于纳米铝表面。
- 在25°C和40°C下评估52周物理稳定性与蛋白负载效率。
- 体外用RAW264.7和DC2.4细胞评估细胞相容性、黏附、内吞及TNF-α表达。
- 免疫后第42天检测OVA特异性IgG1、IgG和IgG2a滴度并与商业佐剂比较。
主要发现
- NAPE在25°C和40°C下维持物理稳定性和高蛋白负载效率长达52周。
- NAPE和NAPE/PSA在RAW264.7和DC2.4细胞中增强细胞黏附和OVA内吞。
- 与Alhydrogel相比,NAPE和NAPE/PSA在RAW264.7和DC2.4细胞中上调TNF-α表达。
- 免疫后第42天,NAPE和NAPE/PSA诱导的IgG1、IgG和IgG2a滴度与商业佐剂相当。
- 免疫后IgG和IgG2a滴度随时间持续升高。
临床怎么用
- NAPE/PSA可作为疫苗佐剂和抗原递送载体用于增强抗原特异性免疫应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adjuvants are pivotal components in vaccine formulations, serving to augment the extensiveness, breadth, and duration of antigen-specific immune responses. Conventional emulsions represent one successful category of vaccine adjuvant, while still with the thermodynamically unstable issue. In this study, a novel polysialic acid (PSA)-loaded Nano-Alum stabilized Pickering emulsion (NAPE or NAPE/PSA) formulation was prepared by anchoring Nano-Alum at the oil/water interface, subsequently integrating PSA and Ovalbumin (OVA) onto the Nano-Alum surface. The findings revealed that the innovative NAPE demonstrated exceptional physical stability and high protein loading efficiency, maintaining these properties for up to 52 weeks at both 25 °C and 40 °C, underscoring the robust stability of the NAPE adjuvant formulation. In vitro assessment indicated that NAPE and NAPE/PSA possess high cellular compatibility, enhancing the cellular adhesion and facilitating the endocytosis of OVA in RAW264.7 and DC2.4 cells, and upregulated TNF-α expression compared with Alhydrogel in RAW 264.7 and DC 2.4 cells. Moreover, both NAPE and NAPE/PSA elicited a potent and enduring OVA-specific immune response, achieving compared IgG1, IgG and IgG2a titers to the commercial adjuvant at day 42, and IgG and IgG2a titers performed a continuous increase trend over time after immunization. These outcomes suggest that NAPE or NAPE/PSA could serve as a potential carrier, offering dual functionalities in adjuvant activity and antigen delivery.
引用
- Yao X, Su D, Ma Z, et al. Adjuvant comprising nano-aluminum hydroxide pickering emulsion with polysialic acid for enhanced vaccination. Vaccine. 2026. PMID: 41500033. doi:10.1016/j.vaccine.2025.128188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。